TABLE 3

Clinical Response to TTM Relative to Baseline

Time FrameVAS-CVAS-SEV
ImprovedNo ChangeWorsenedImprovedNo ChangeWorsened
No. of PatientsMean VAS-C%No. of PatientsMean VAS-C%No. of PatientsMean VAS-C%No. of PatientsMean VAS-SEV%No. of PatientsMean VAS-SEV%No. of PatientsMean VAS-SEV%
1 to 3 mo (n = 454)31631.1869.61092.9524.029−23.156.417631.9338.82181.2448.060−25.1313.2
3 to 6 mo (n = 459)41244.0689.8343.887.413−28.922.829848.2964.91301.3428.331−23.426.8
6 to 9 mo (n = 299)27656.3692.3181.446.05−23.61.722949.6776.6540.7818.116−235.4
>9 mo (n = 202)19569.7296.5422.03−26.671.518161.2289.6161.257.95−342.5
  • ≥10% change in VAS from baseline defined as threshold for meaningful clinical response.